Genenta appoints industry veteran Tim Obara to lead

MILAN, Italy and NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of immunogenic hematopoietic stem cell therapy for cancer, announces the appointment of Tim Obara, a highly experienced healthcare business executive, as Vice President of Business Development.

Tim has significant experience in a wide range of therapeutic areas and with global responsibility. He joins Genenta from the University of Pennsylvania’s gene therapy program, where he was executive director of research operations. He previously held business development roles at Amicus Therapeutics, AstraZeneca, GSK and Singapore-based Tessa Therapeutics.

Pierluigi Paracchi, CEO of Genenta Science, said, “I am delighted to welcome Tim to Genenta. Tim brings extensive business experience, particularly identifying, evaluating and closing late-stage business development and R&D opportunities. I look forward to working closely with Tim as Genenta continues to develop Temferon™ through clinical trials and expand our technology platform into other opportunities in the solid tumor market.

Tim added, “It’s an exciting time to join Genenta to identify and pursue business development opportunities that help realize the full potential of Temferon™ and Genenta’s proprietary technology platform. I look forward to to work with the talented Genenta team and leverage my experience across the healthcare industry and academia to continue to create and deliver value to the company and investors.”

About Genenta Science

Genenta (www.genenta.com) is a clinical-stage biotechnology company pioneering the development of proprietary hematopoietic stem cell-based gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumour-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes – TEM). Temferon™, which is undergoing a Phase 1/2a clinical trial in patients newly diagnosed with glioblastoma multiforme harboring an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology, designed to reach solid tumors, induce a durable immune response not limited to preselected tumor antigens or type, and avoid systemic toxicity, which are some of the major unresolved challenges in immuno-oncology.

Forward-looking statements

The statements in this press release contain “forward-looking statements”, within the meaning of the United States Private Securities Litigation Reform Act of 1995, which are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements in this press release can be identified by the use of words such as “anticipate”, “believe”, “contemplate”, “could”, “estimate”, “expect”, “have the ‘intent’, ‘seek’, ‘may’, ‘could’, ‘plan’, ‘potential’, ‘predict’, ‘project’, ‘suggest’, ‘target’, ‘aim’, ‘should’, ‘shall’ , “would” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta’s current expectations and are subject to uncertainties, risks and assumptions. inherent risks that are difficult to predict, including risks related to the completion and timing of the Phase 1/2a clinical trial or any study relating to the treatment of patients with glioblastoma multiforme who carry an MGMT gene promoter unmethylated (uMGMT-GBM) future events which may not prove to be accurate. These and other uncertainties are more fully described in the section titled “Risk Factors” in the Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission. . The forward-looking statements contained in this announcement are made as of this date, and Genenta Science SpA (GNTA) undertakes no obligation to update such information except as required by applicable law.

Investor Relations – LifeSci Advisors:
Mary-Ann Chang, CFA
+44 7483 28 48 53
[email protected]
Genenta Media:
Tiziana Pollio
+39 3482315143
[email protected]

About Gregory Lewis

Check Also

Business Development, Size, Share and Opportunities 2028 – Indian Defense News

The MarketQuest.bizon Global IQF Food Market the research examines current industry and market trends, …